The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Inefficient Prescribing Costs Billions of Healthcare Dollars

Inefficient Prescribing Costs Billions of Healthcare Dollars

May 11, 2016 • By Andrew M. Seaman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—In the U.S. between 2010 and 2012, nearly $73 billion was spent on brand name medications instead of less expensive alternatives, according to a new study.

You Might Also Like
  • Drug Company Gifts Linked to Doctors’ Prescribing Habits
  • Can Anything Contain Drug Costs in the U.S.?
  • Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

A large portion of that money was spent by patients, the researchers found.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Prescription drug prescribing during the time of this paper was not efficient and still isn’t efficient,” says lead author Dr. Michael Johansen, of Ohio State University in Columbus. “The number we’re spending on prescription drugs is really large. At least from what this paper shows, patients are bearing a disproportionate amount of the inefficiencies in our prescribing.”

One way to make prescribing more efficient is to order the generic form of the brand name drug. Another, less widely accepted approach is known as therapeutic substitution, in which the patient receives a drug in the same class, but not necessarily the same drug.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

To see how much could possibly be saved with therapeutic substitution, Johansen and his co-author Dr. Caroline Richardson of the University of Michigan in Ann Arbor analyzed 2010–2012 data on 107,132 medication users.

As reported online on May 9 in JAMA Internal Medicine, about 62% of participants were using prescription drugs, and about a third were using a medication that was eligible for therapeutic substitution.

Of the $760 billion spent on prescription drugs during the study period, about $73 billion may have been unnecessarily spent on brand name drugs, the researchers found.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Nearly $25 billion of the $175 billion that patients paid out-of-pocket for their drugs during that time might have been saved by therapeutic substitutions.

The key to moving toward therapeutic substitution is to coordinate with doctors, says Johansen, because in some cases a patient may need a specific generic drug for a specific reason.

His concerns are echoed in an editorial by Dr. Joseph Ross, JAMA Internal Medicine associate editor and associate professor at Yale University in New Haven, Conn.

“To achieve the benefits of within-class substitution, we need wider adoption of systematic protocols, aligned with physician judgment, as to when such substitutions are beneficial and when not,” he writes.

Johansen thinks it will take a lot of different interventions at different levels to overcome reluctance to implement therapeutic substitution, but policy efforts will probably be helpful.

“Essentially the feeling you get with this is very similar to how people felt when generics were coming out,” he says. But, he points out, “The acceptance of generic drugs has improved.”

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Pharma Co. News Tagged With: generic drugs, Health care, Prescription drugs

You Might Also Like:
  • Drug Company Gifts Linked to Doctors’ Prescribing Habits
  • Can Anything Contain Drug Costs in the U.S.?
  • Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment
  • Docs & Patients Should Remember to Use Generics

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.